News Releases

Tokyo, April 10, 2012,Taiho Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Masayuki Kobayashi) announced that our partner in Europe, Nordic Group BV (Head office: Hoofddorp, the Netherlands ; CEO and Managing Director: Drs. Hans Schram) has just started marketing of Teysuno_® , which has been developed by Taiho Pharmaceutical Co., Ltd., in the United Kingdom following its launches in Sweden, Denmark, Norway and Finland, and will be progressively introduced in the other European Union countries before the end of the year.

Teysuno, a novel oral anti-cancer agent, received Marketing Authorization from the EMA for the treatment of adults with advanced gastric cancer when given in combination with cisplatin (March 14, 2011). The NHS price has been approved and is fully reimbursed.

Nordic Group BV has an exclusive right to commercialize Teysuno in the EU and other selected European Countries under the agreement with Taiho Pharmaceutical Co., Ltd.

The Nordic Group is a privately owned, fast growing, fully integrated, pan-European Pharmaceutical company, with a strong focus on the development and commercialization of niche hospital and orphan products and services that cater to the specific needs of clients and patients. In addition to its sales and marketing companies in 13 European countries, operating under the name of Nordic Pharma and Nordic Drugs, the Nordic Group operates as well a number of specialized Pharmaceutical Services companies, specialized in product development, manufacturing, supply logistics, clinical studies and regulatory activities. These companies are operating under the name of Prague Clinical Services, QPharma, Disphar and Indeus. Since its creation, Nordic has enjoyed an average growth of 20% in revenues, and it pursues its expansion through organic growth and strategic collaborations.

Additional information can be obtained by visiting Nordic Group's website at www.nordicpharmagroup.com .